Tissue Regenix acquires CellRight Technologies in $30M deal: 6 things to know Featured

Written by  Megan Wood | Thursday, 10 August 2017 17:51
Social sharing

Tissue Regenix acquired CellRight Technologies today, according to MASS DEVICE.

Here are six things to know:


1. The acquisition, which closed today, totaled $30 million.


2. Tissue Regenix hopes the acquisition will boost its U.S. presence by more than doubling its sales in the area.


3. Tissue Regenix creates technology designed to regenerate tissue via a scaffold composed of decellularized animal and human tissue.


4. CellRight Technologies developed bone technology that aligns with Tissue Regenix's soft tissue-based platform.


5. Tissue Regenix plans to introduce its OrthoPure HT decellularized human tendon to the U.S. market in early 2018.


6. MASS DEVICE reports Tissue Regenix funded the acquisition with a $52 million floatation of 400 million shares.


More articles on devices:
Lane Hale named President & CEO of ECA Medical Instruments
Dr. Patrick Noud 1st to use Arrow Prime Dual-Platform Total Shoulder System: 5 highlights
FDA clears Stimwave's StimQ Peripheral Nerve Stimulator, enabling full-body MRI scan: 4 points

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months